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Background: The primate lentiviruses, human immunodeficiency virus types 1
and 2 (HIV-1 and HIV-2) and simian immunodeficiency virus (SIV), encode a
conserved accessory gene product, Nef. In vivo, Nef is important for the
maintenance of high virus loads and progression to AIDS in SIV-infected adult
rhesus macaques. In tissue culture cells expressing Nef, this viral protein
interacts with a cellular serine kinase, designated Nef-associated kinase.
Results: This study identifies the Nef-associated kinase as a member of the p21-
activated kinase (PAK) family of kinases and investigates the role of this Nef-
associated kinase in vivo. Mutants of Nef that do not associate with the cellular
kinase are unable to activate the PAK-related kinase in infected cells. To
determine the role of cellular kinase association in viral pathogenesis, macaques
were infected with SIV containing point-mutations in Nef that block PAK
activation. Virus recovered at early time points after inoculation with mutant virus
was found to have reverted to prototype Nef function and sequence. Reversion
of the kinase-negative mutant to a kinase-positive genotype in macaques infected
with the mutant virus preceded the induction of high virus loads and disease
progression.
Conclusions: Nef associates with and activates a PAK-related kinase in
lymphocytes infected in vitro. Moreover, the Nef-mediated activation of a PAK-
related kinase correlates with the induction of high virus loads and the
development of AIDS in the infected host. These findings reveal that there is a
strong selective pressure in vivo for the interaction between Nef and the PAK-
related kinase.
Introduction
The nef gene of human immunodeficiency virus types 1 and
2 (HIV-1 and HIV-2) and simian immunodeficiency virus
(SIV) encodes a 27–34 kDa, myristylated and phosphor-
ylated protein that is expressed in the early stage of the viral
replication cycle (reviewed in [1–3]). Although Nef is dis-
pensable for productive infection in T-cell lines, this viral
accessory protein plays an important role in the induction of
acquired immune deficiency syndrome (AIDS) in SIV-
infected rhesus macaques [4]. Studies addressing Nef func-
tion in tissue culture cells [5–7], transgenic mice [8] and
SIV-infected macaques [9] suggest that this viral protein
alters a cell signalling pathway(s). In T-cell cultures, Nef
decreases the levels of the CD4 antigen on the cell surface
[10–12] and increases virion infectivity [13–15] (reviewed in
[1–3]). In transgenic mice expressing HIV-1 Nef, thymo-
cytes display altered cell activation responses [8]. Rhesus
macaques infected with SIVmac239nefYE, a clone contain-
ing two point mutations that generate a novel SH2-like
domain near the amino terminus of Nef, exhibit an acute,
fatal, gastrointestinal tract disease accompanied by T-cell
proliferation in several lymphoid organs [9]. This mutant nef
also transforms murine NIH3T3 cells in vitro [9]. Taken
together, these observations imply that Nef has a role in
perturbing a cell-activation pathway(s) which is presumed
to influence the level of viral replication in the host and/or
cause dysfunction of cells in the immune system.
An important approach to study Nef function(s) has been to
identify and characterize cellular proteins that interact with
this viral protein. Accordingly, Nef has been reported to
bind CD4 [7,16], Lck [7,17], p53, mitogen-activated protein
(MAP) kinase [7], the SH3 domains of Hck and Lyn
[18,19], c-Src [9] and b-COP [20]. However, most of these
reports lack experiments demonstrating that Nef and these
various cellular proteins form complexes in permissive cells
infected with virus; they also lack genetic analysis using
viruses bearing mutations in nef that would establish the
significance of such protein–protein interactions. To
address these limitations, we have previously shown that
Nef expressed in HIV-1-infected lymphocytes associates
with a cellular serine kinase (Nef-associated kinase) which
phosphorylates two cellular proteins, p62 and p72, that co-
immunoprecipitate with Nef [21]. Additionally, mutation
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analysis demonstrated that amino-terminal myristylation
and the central conserved domain of Nef were important
for the Nef-associated kinase activity [22].
Results
Characterization of the Nef-associated kinase
To identify the cellular kinase activity that associates with
Nef, we screened numerous commercially available
antibodies to known signal transduction molecules for their
ability to recognize two cellular proteins, p62 and p72, that
coimmunoprecipitate with Nef from lymphoid cells
infected with HIV-1 or SIV. During this screening process,
an antibody directed against a p21-activated kinase (PAK)
was found to immunoprecipitate proteins of 62 and 72 kDa
in an in vitro kinase assay. The PAKs are highly conserved,
ubiquitous serine kinases important for the transduction of
external signals to the nucleus [23–28]. These kinases,
ranging in size from 62 to 70 kDa, become activated and
autophosphorylate after they bind the p21 Rho-like GTP-
binding proteins, Rac-1 and Cdc42Hs [23–31].
A polyclonal antiserum specific for the amino-terminal 20
amino acids of PAK-1 from rat brain was used to immuno-
precipitate PAK from uninfected CEMx174 cells and cells
chronically infected with SIVmac239nef+ (a molecular  SIV
clone containing a prototype nef gene). In vitro kinase assays
performed on these immunoprecipitates from infected cells
revealed two phosphorylated proteins of 62 and 72 kDa
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Figure 1
Association between Nef and a PAK-related
kinase. (a) An in vitro kinase assay was
performed on anti-SIV Nef (lanes 1 and 3) and
anti-PAK (lanes 2 and 4) immunoprecipitates
from uninfected (lanes 1 and 2) and
SIVmac239nef+-infected (lanes 3 and 4)
CEMx174 extracts, as previously described
[21]. Nef was immunoprecipitated with a
monoclonal antibody directed against SIV Nef
(17.2) and PAK was immunoprecipitated with a
polyclonal serum directed against the amino-
terminal 20 amino acids of rat PAK-1. Proteins
were separated by SDS–PAGE on a 12 % gel
and transferred to PVDF membranes.
Radiolabeled proteins were visualized by
autoradiography. The positions of p62, p72
and p25 are indicated by arrows on the left.
Phosphorylated bands in the 46 kDa range
were non-specific in these
immunoprecipitations. (b) Immunological
detection of Nef in anti-PAK
immunoprecipitates. The PVDF filter from (a)
was probed with the anti-Nef monoclonal
antibody (17.2) as described in Materials and
methods. The positions of Nef and
immunoglobulin G (IgG) heavy (H) chains are
indicated on the right. (c) Specificity of the anti-
PAK antibody. Kinase assays were performed
on anti-Nef (lanes 1 and 2) and anti-PAK (lanes
3 and 4) immunoprecipitates that had been
preincubated with (+, lanes 2 and 4) or without
(–, lanes 1 and 3) a competitor peptide
corresponding to the amino terminus of PAK-1
that is recognized by the anti-PAK antiserum.
(d) Re-immunoprecipitation of PAK from HIV-1
Nef immunoprecipitates. A kinase assay was
performed on a Nef immunoprecipitate from
HUT78 cells chronically infected with the
HIV-1SF11114 strain (lanes 1 and 2). Proteins
associated with Nef were released from the Nef
immunoprecipitates with kinase extraction
buffer [21] containing 0.1 % SDS. The
supernatant was subjected to two successive
incubations with protein A–Sepharose; lane 3
represents the pellet from the second protein
A–Sepharose clearance. The supernatant was
split three ways and immunoprecipitated with
anti-SIV Nef control (lane 4) antibodies, anti-
PAK-1 (lane 5) antibodies, or anti-human
PAK65 (hPAK65, lane 6) antibodies. Lanes
2–6 represent a 5 day autoradiographic
exposure; lane 1 represents an overnight
exposure of lane 2. (e) Re-immunoprecipitation
of PAK from SIV Nef immunoprecipitates. A
PAK re-immunoprecipitation analysis was
performed on a SIV Nef immunoprecipitate
from CEMx174 cells chronically infected with
SIVmac239nef+ as described in (d): lanes 1
and 2, SIV Nef immunoprecipitates; lane 3,
second protein A–Sepharose clearance; lane
4, anti-HIV-1 matrix protein (MA) control; lane
5, anti-PAK-1; lane 6, anti-human PAK65
(hPAK65). Lanes 2–6 represent a 5 day
autoradiographic exposure; lane 1 represents
an overnight exposure of lane 2.
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(Fig. 1a, lane 4), which are hyperphosphorylated forms of
the 62 and 72 kDa proteins observed in PAK immunopre-
cipitates from uninfected cell lines (Fig. 1a, lane 2). Impor-
tantly, these phosphorylated proteins were similar in size to
the two proteins (p62 and p72) that co-immunoprecipitated
with Nef (Fig. 1a, lane 3). In the anti-Nef immunoprecipi-
tate, p62 and p72 were the major and minor phosphorylated
species, respectively (Fig. 1a, lane 3), whereas p72 was the
major and p62 was the minor phosphorylated species in the
anti-PAK-1 immunoprecipitate (Fig. 1a, lane 4). In unin-
fected CEMx174 cells, a phosphorylated protein migrating
slightly faster than p62, and a phosphorylated protein of
25 kDa (p25) were detected in the anti-PAK-1 immunopre-
cipitate (Fig. 1a, lane 2). Neither PAK nor p25 was found in
immunoprecipitates from infected cells (Fig. 1a, lane 4).
The identity and significance of p25 for Nef-mediated PAK
activation remain to be elucidated.
To determine whether the hyperphosphorylation of p72 in
SIV-infected lymphocytes was PAK-specific, kinase assays
were performed on Nef and PAK immunoprecipitates
using antibodies that were preincubated with a PAK-1
competitor peptide (Fig. 1c). This peptide represents the
epitope recognized by the anti-PAK-1 antibody. Because
p72 was not phosphorylated after anti-PAK sera was prein-
cubated with the PAK-1 competitor peptide, the hyper-
phosphorylation of p72 in SIV-infected cells was indeed
PAK-specific.
Identification of the Nef-associated kinase as a 
PAK-related kinase
To determine whether Nef and PAK associate in infected
cells, an immunoblot analysis (Fig. 1b) using a Nef-
specific antibody probe was performed on immunoprecip-
itates produced with anti-Nef and anti-PAK-1 antibodies
(Fig. 1a). Nef was detected in both the anti-Nef and anti-
PAK-1 immunoprecipitates from cells infected with
SIVmac239nef+ (Fig. 1b, lanes 3 and 4). Nef was not
detected in uninfected CEMx174 cells (Fig. 1b, lanes 1
and 2). Using the PAK-1-specific antibody to probe the
anti-Nef and anti-PAK-1 immunoprecipitates described
above, we detected p62 in the anti-PAK-1 immunopre-
cipitates from uninfected and infected cells (data not
shown). However, it was difficult to demonstrate the
presence of p62 in the anti-Nef immunoprecipitate of
cells infected with SIVmac239nef+ (data not shown); this
could result from the small proportion of PAK-1 (or a
PAK-related protein) that is associated with Nef in
infected cells. These results indicate that Nef forms a
complex with PAK-1 (or a PAK-related protein) in
infected lymphoid cells.
To confirm that Nef associates with a PAK-related kinase,
a re-immunoprecipitation analysis was performed on a
HIV-1 Nef immunoprecipitate (Fig. 1d). Anti-PAK anti-
bodies recognized p62, which was released from the HIV-1
Nef immunoprecipitates (Fig. 1d,e). Similar results were
obtained with SIV Nef immunoprecipitates (Fig. 1e). Note
that p62 was not observed in the lane containing the non-
specific antibody control (Fig. 1d,e; lane 4). These results
confirm data from a recent study [32] showing that a HIV-
1 Nef fusion protein expressed by a retroviral vector in T
cells associates with a member of the PAK family of pro-
teins. Taken together, these studies show that Nef associ-
ates with a PAK-related protein in cells infected with
HIV-1 or SIV.
Comparison of p62 and p72 by analysis of
phosphopeptide maps
The relationship between p62 and p72 from anti-Nef and
anti-PAK-1 immunoprecipitates was investigated by phos-
phopeptide mapping. Proteins immunoprecipitated with
anti-Nef and anti-PAK-1 antibodies were radiolabeled in an
in vitro kinase assay and subjected to SDS–PAGE; 32P-
labeled bands corresponding to p62 and p72 were isolated
and subjected to partial protease cleavage with
chymotrypsin. The phosphopeptide maps of p62 from anti-
SIV Nef and anti-PAK-1 immunoprecipitates were similar,
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Figure 2
Phosphopeptide maps of p62 and p72. Partial chymotryptic
digestion was performed on bands corresponding to p62 (lanes 1
and 2) and p72 (lanes 3 and 4) from SIV Nef (lanes 1 and 2) and
PAK (lanes 2 and 4) immunoprecipitates. The arrows indicate the
positions of the major partial peptide cleavage products for p62 (left
side) and p72 (right side).
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indicating that p62 associated with SIV Nef and PAK-1 was
highly related (Fig. 2, lanes 1 and 2). Additionally, the
phosphopeptide maps of p72 from anti-SIV Nef and anti-
PAK-1 immunoprecipitates were also similar (Fig. 2, lanes
3 and 4). However, it is important to note that the partial
proteolytic cleavage maps for p62 and p72 are distinct (Fig.
2). Similar results were obtained when phosphopeptide
maps of p62 and p72 from cells infected with SIV or HIV-1
were compared after partial proteolysis with staphylococcal
V8 protease (data not shown). Taken together, these results
indicate that p62 and p72 are different molecules.
Mutants of Nef defective for kinase association do not
activate PAK
Previously, we have shown that mutation of two highly
conserved arginine residues at positions 137 and 138 of
Nef from SIVmac239 abrogates association with the Nef-
associated kinase in transient expression assays [22].
These point mutations and a large deletion of nef [4] were
introduced into the molecular clone of SIVmac239nef+ to
produce the two clones SIVmac239nefRR–LL (in which the
arginine residues are replaced by leucines) and
SIVmac239∆nef, respectively. The synthesis and stability
of the R137R138–LL mutant Nef in cells infected with
SIVmac239nefRR–LL were indistinguishable from those of
the prototype Nef in cells infected with SIVmac239nef+
(data not shown), but the ability of the mutant Nef to
associate with and activate PAK was abrogated (Fig. 3,
compare lanes 3 and 4 with lanes 5 and 6). The cellular
proteins p62 and p72 were phosphorylated by the Nef-
associated kinase in cells chronically infected with
SIVmac239nef+ (Fig. 3, lanes 3 and 4) but not in cells
infected with SIVmac239nefRR–LL (Fig. 3, lanes 5 and 6)
or SIVmac239∆nef (Fig. 3, lanes 9 and 10). Nef was not
detected by immunoblot analysis of PAK immunoprecipi-
tates from cells infected with SIVmac239nefRR–LL or
SIVmac239Dnef (data not shown). Immunoblot experi-
ments using anti-PAK-1 antibodies revealed that equal
amounts of PAK were detected in all PAK immunoprecip-
itates (data not shown). Interestingly, infection of
CEMx174 cells with Nef mutants results in hypophospho-
rylation of p72 and a loss of basal PAK activity (compare
lanes 6 and 10 with lane 4). The mechanism by which this
loss of PAK activation occurs during virus infection has not
been elucidated. Nevertheless, the hyperphosphorylation
of p72 is a marker for the Nef-mediated activation of the
PAK-related kinase. These data, based on a combination
of genetic and biochemical experiments, demonstrate that
the ability of Nef to activate the PAK-related kinase in
productively infected lymphoid cells is linked to its ability
to bind the PAK-related kinase.
Because Nef from T-cell lines infected with HIV-1 strain
SF2 (HIV-1SF2) interacts with the Nef-associated kinase
[21], we examined the activation of the PAK-related
kinase in cells infected with HIV-1 (Fig. 3, lanes 7 and 8).
In vitro kinase assays revealed that the PAK-related kinase
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Figure 3
Analysis of HIV and SIV Nef mutants for activation of PAK. Kinase
assays were performed on anti-SIVmac239 Nef (Nef, lanes 1,3,5 and
9), anti-HIV-1SF2 Nef (lane 7) and anti-rat PAK-1 (PAK, lanes 2,4,6,8
and 10) immunoprecipitates from uninfected CEMx174 cells (lanes 1
and 2), CEMx174 cells chronically infected with SIVmac239nef+ (SIV
Nef+, lanes 3 and 4), SIVmac239nefRR–LL (NefRR–LL, lanes 5 and 6) or
SIVmac239Dnef (SIV DNef, lanes 9 and 10) or HUT78 cells
chronically infected with HIV-1SF2 (HIV-1 Nef, lanes 7 and 8). The
positions of migration of PAK from uninfected cells, and of p62 and
p72, are indicated on the left.
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Viral loads in SIV-infected rhesus macaques. The levels of SIV p27gag
were measured by enzyme-linked immunosorbent assay (ELISA) from
the plasma of monkeys infected with SIVmac239nef+ (26084 and
27098), SIVmac239nefRR–LL (26767 and 26969), or SIVmac239Dnef
(26873 and 26939) at the indicated weeks post-inoculation.
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was activated in the T-cell line HUT78 chronically infected
with HIV-1SF2. Thus, the property of Nef-mediated activa-
tion of the PAK-related kinase in lymphoid cells is shared
by HIV-1 and SIV.
In vivo analysis of SIV Nef mutants
To examine the role of the association between Nef and
the PAK-related kinase in viral pathogenesis, we com-
pared virus load and disease potential of
SIVmac239nefRR–LL with those of the non-pathogenic
clone SIVmac239Dnef and the pathogenic clone
SIVmac239nef+ in juvenile rhesus macaques. Figure 4
shows that plasma virus load in macaques infected with
SIVmac239nefRR-LL (macaques 26767 and 26969) or the
non-pathogenic clone SIVmac239Dnef (macaques 26873
and 26939) was below the level of detection in the first 4
weeks after infection, whereas viral antigen was readily
detected in this acute stage of infection in plasma from
macaques inoculated with SIVmac239nef+ (macaques
26084 and 27098). After 4 weeks, there was an increase in
the level of viral antigen in plasma from macaques inocu-
lated with SIVmac239nefRR–LL. However, in macaques
infected with SIVmac239∆nef, plasma antigen remained
below the level of detection (Fig. 4).
The increase in plasma virus load in the two macaques
after 4 weeks of infection with SIVmac239nefRR–LL
suggested that the mutation in nef may have reverted. At 2
and 4 weeks after inoculation, Nef was analyzed from
virus isolated from the peripheral blood mononuclear cells
(PBMCs) of both of these animals. Immunoprecipitation
studies revealed a low level of Nef-associated kinase activ-
ity from virus recovered at 2 weeks (Fig. 5a, lanes 6 and 7).
A striking enhancement in the ability of Nef to associate
with the kinase was observed from virus collected at 4
weeks (Fig. 5a, lanes 8 and 9). Thus, the ability of Nef to
associate with the kinase had been restored during the
acute stage of infection in the two animals inoculated with
SIVmac239nefRR–LL. Furthermore, both animals exhibited
a progressive increase in virus load (Fig. 4) and developed
clinical signs of disease (Table 1). To determine the
nature of the genetic changes in the viruses showing this
phenotypic reversion, DNA was isolated from PBMCs col-
lected from the two SIVmac239nefRR–LL-infected mac-
aques at 2 and 4 weeks after inoculation, and the nef gene
was amplified by the polymerase chain reaction (PCR) and
sequenced. All nef clones from the 2 week samples had the
mutant leucine codons at positions 137 and 138. In con-
trast, the leucine (mutant) codon at position 138 had been
replaced with a codon for arginine in most (19/20 PCR
clones) nef sequences from both animals at 4 weeks (Table
2). Moreover, both leucine (mutant) codons were replaced
by arginine codons at positions 137 and 138 in several
(6/11) of the nef clones from macaque 26767. By 8 weeks,
almost all (15/16) of the nef sequences had the prototype
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Figure 5
Functional and genetic changes in Nef from macaques infected with
SIVmac239nefRR–LL, showing phenotypic reversion. A polyclonal anti-
SIV Nef antibody was used to immunoprecipitate cellular extracts from
uninfected CEMx174 cells (–, lane 1), or from CEMx174 cells that
were either chronically infected (lanes 2 and 3) or acutely infected
(lanes 4 and 5) with SIVmac239nef+ (+, lanes 2 and 4),
SIVmac239nefRR–LL (RR–LL, lanes 3 and 5), or with virus recovered 2
or 4 weeks after inoculation from the PBMCs of macaques 26767
(lanes 6 and 8) or 26969 (lanes 7 and 9). In vitro kinase assays were
performed on all of the immunoprecipitates.
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Table 1
Clinical summary
Monkey Virus Time of death Number of CD4+ cells Pathological findings
26767 SIVmac239nefRR–LL 28 weeks Decreased Multiple malignant abdominal and  spinal lymphonas,
lymphadenopathy and pneumonia (Pneumococcus carinii)
26969 SIVmac239nefRR–LL 50 weeks Decreased Wasting, diarrhea, lymphadenopathy, splenic lymphoid
hyperplasia and multiple opportunistic infections (Trichonomas, 
Giardia, Blastocystis hominis and Entamoeba coli)
26084 SIVmac239nef+ 51 weeks Decreased Wasting, diarrhea, lymphadenopathy and pneumonia
27098 SIVmac239nef+ 87 weeks Decreased Wasting, diarrhea and lymphadenopathy
Nef amino acids, with arginines at positions 137 and 138.
Interestingly, the reversion of leucine at position 138 to
arginine occurred before the leucine to arginine reversion
at position 137 (Table 2). This pattern of genetic change
suggested that the arginine at position 138 in the di-argi-
nine motif is more important for Nef function. This
finding is consistent with previous mapping studies with
HIV-1SF2 Nef, in which the second arginine of the di-argi-
nine motif (positions 109 and 110) was shown to be critical
for the association between Nef and the cellular kinase
[22]. Although the first arginine residue of the di-arginine
motif was not critical for the  Nef–kinase association (see
macaque 26969 at the 4 week time point in Fig. 5a and
Table 2), this residue may be important for maintaining an
optimal structure for kinase association.
Clinical signs of disease were monitored to assess the
pathogenic potential of these viruses. Macaques 26767 and
26969, which were inoculated with SIVmac239nefRR–LL,
and macaques 26084 and 27098, which received the proto-
type virus SIVmac239nef+, developed simian AIDS and
were euthanized at 28, 50, 51 and 87 weeks after infection,
respectively (Table 1). Analysis of the cell-associated virus
load in PBMCs and lymph nodes, and measurements of
cell-free virus in plasma, revealed that all four animals con-
tained high amounts of infectious virus in the period imme-
diately prior to and at the time of necropsy (data not
shown). Pathological and histopathological examination of
several organs collected at necropsy confirmed that these
macaques had signs of simian AIDS, including
lymphadenopathy and infection with one or more
opportunistic pathogens (Table 1). Control macaques
inoculated with SIVmac239Dnef had low viral loads and no
clinical abnormalities for an observation period of over one
year (see also [4]). Taken together, the above results
demonstrate that there is strong selective pressure for
restoring the ability of Nef to activate PAK in vivo, and
that activation of a PAK-related kinase correlates with the
induction and maintenance of high viral loads and disease
progression.
Discussion
Nef activates a PAK-related kinase
In this study, Nef from lymphoid cells infected with HIV-1
or SIV was shown to associate with and activate a cellular
serine kinase in the PAK family. Nef forms a complex with
a PAK or PAK-related protein in infected lymphoid cells,
as demonstrated by the co-immunoprecipitation of Nef
with PAK in PAK immunoprecipitates (Fig. 1b), the re-
immunoprecipitation of PAK released from Nef immuno-
precipitates (Fig. 1d,e), and the proteolytic mapping
studies of p62 and p72 from Nef and PAK immunoprecipi-
tates (Fig. 2). Furthermore, these findings are supported
by genetic studies using a transdominant mutant of PAK65
that blocked Nef-mediated PAK activation in a transient
expression assay (data not shown). Recently, a highly con-
served motif in the amino-terminus of PAK65 has been
shown to be responsible for interacting with the
Rac1/Cdc42 GTPases; this regulatory domain is found in a
number of cellular kinases [33]. Thus, it is possible that the
Nef-associated kinase is either a known PAK, or a kinase
that shares the amino terminus of PAK-1. Further studies
are required to determine the exact relationship of p62 and
p72 with the PAK family of serine kinases.
Nef-associated kinase and viral pathogenesis
This study demonstrates that a mutation in Nef, which
abrogates the association with, and activation of, a PAK-
related kinase, rapidly reverts to a PAK activation-positive
phenotype and genotype in vivo (Fig. 5). Importantly, this
reversion correlates with the induction of high viral loads
(Fig. 4) and progression of infected macaques to disease
(Table 1). Although a previous study demonstrated that
reversion of a premature stop codon in the SIV Nef trans-
lation frame correlated with increased virus load and
development of disease [4], our report links a specific bio-
chemical function — the ability of Nef to associate with
and activate a PAK — to induction of high viremia and
pathogenesis. The precise relationship between virus
load and the rate of disease progression in macaques
infected with molecular clones of SIVmac is not clear. In a
previous study, macaques infected with SIVmac239/nef-
stop, a clone with a premature translational termination
codon in nef, showed a similar range of times until death
as macaques infected with SIVmac239nef+ [4,34].
Complex host factors (such as the genetics of the host’s
immune responses) as well as potential cofactors (such as
opportunistic pathogens) can influence virus load and
disease progression.
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Table 2
Analysis of viral DNA sequences in macaque PBMCs
Macaque 26969 Macaque 26767
Time after Number of Sequence Number of Sequence
inoculation clones clones
2 weeks 8 CTA CTA = L,L 8 CTA CTA = L,L
4 weeks 8 CTA CGA = L,R 4 CTA CGA = L,R
1 CTA CTA = L,L 6 CGA CGA = R,R
1 CCA CGA = P,R
8 weeks 7 AGA AGA = R,R 1 CGA CGA = R,R
1 CTA CTA = L,L 7 AGA AGA = R,R
nef genes from macaques (26767 and 26969) infected with
SIVmac239nefRR–LL were sequenced from DNA isolated from PBMCs
collected at 2, 4 and 8 weeks post-inoculation. The codons for amino-
acid residues 137 and 138 are shown, and the amino acids they
encode are indicated in single-letter code. Numbers indicate the
number of nef clones with the respective sequence. The input virus,
which was negative for cellular kinase association had the sequence
CTA CTA, which encodes leucine (L) residues, at positions 137 and
138, whereas the corresponding sequence of the SIVmac239nef+
prototype virus was AGA AGA, which encodes arginine (R) residues.
Activation and Nef functions
Perturbation of a key cell-activation pathway(s) could
explain the seemingly disparate roles attributed to Nef,
such as downregulation of cell-surface CD4 and enhance-
ment of virion infectivity (reviewed in [1–3]). The effects
of Nef on cellular activation may influence the levels of
CD4 surface expression and/or transcription of lymphoid
cell genes; such changes mediated by Nef may lead to
dysfunction of helper T cells and subsequent immunode-
ficiency. The effects of Nef on infectivity may be a conse-
quence of changes in phosphorylation of a viral structural
protein(s) during particle assembly, which is a process pre-
sumed to involve components of intracellular architecture.
For example, Nef activation of PAK may influence, either
directly or indirectly, phosphorylation of the matrix
protein (MA) in the viral core during virion morphogene-
sis. Modification of MA by phosphorylation is important
for viral infectivity [35–37]. Additionally, the enhance-
ment of virion infectivity and transcriptional activation of
the provirus are expected to produce high virus load,
which is associated with the depletion of CD4 cells and
disease progression [38].
Nef structure and function
The di-arginine motif, which reverts in vivo, is located
within the conserved central domain of Nef that is impor-
tant for kinase association. The importance of the con-
served central region of Nef for viral pathogenesis has also
been highlighted by the finding that SIVmac clone 8,
which encodes a Nef protein with a four amino-acid dele-
tion, reverts from an attenuated to a pathogenic pheno-
type by the duplication of sequences flanking the deletion
[39]. Another intriguing report, which focuses attention on
the conserved central region of Nef, describes a group of
long-term nonprogressors infected with a strain of HIV-1
that contains a deletion in this region ([40], see also [41]).
Further studies are required to precisely define the
domain of Nef responsible for PAK activation in the
context of the structural model recently deduced by
nuclear magnetic resonance spectroscopy [42] and X-ray
crystallography [43]. It is intriguing to note that the X-ray
crystallographic structure of Nef [43] suggests the impor-
tance of the second arginine in the central di-arginine pair
of the conserved domain for both HIV-1 [22] and
SIVmac239 (this study). Accordingly, knowledge of the
structure and function(s) of the PAK(s) interacting with
Nef will not only help to elucidate the key intracellular
signalling events in the mechanism of viral pathogenesis,
but also may be used to design novel drugs that inhibit
virus replication and block progression to AIDS.
Conclusions
This study demonstrates that both HIV-1 and SIV Nef
associate with and activate a PAK-related kinase in produc-
tively infected lymphocytes. Furthermore, mutations of
Nef that abrogate cellular kinase association do not activate
PAK. Using the SIV/rhesus macaque model for AIDS
pathogenesis, we found that there is a strong selective pres-
sure for the ability of Nef to associate with the PAK-related
kinase. Moreover, the reversion of Nef from a PAK activa-
tion-defective to a PAK activation-positive phenotype cor-
relates with the induction of high virus loads and disease
progression in infected macaques. These results should
facilitate the development of novel therapeutic approaches
to inhibit HIV replication and prevent AIDS progression.
Materials and methods
Cells, virus and antibodies
CEMx174, a T-/B-hybrid human lymphoid cell line, permissive for
replication of SIVmac clones, was obtained from J. Hoxie. CEMx174
cells chronically infected with SIVmac clones and HUT78 cell cultures
chronically infected with HIV-1SF2 were derived as outgrowths of acute
infection with the respective virus and were cultured as described previ-
ously [21]. Human rhabdomyosarcoma cells (RD-4), obtained from the
ATCC, were maintained in Dulbecco’s minimal essential medium con-
taining 10 % fetal bovine serum (FBS), 1 % glutamine and 1 % peni-
cillin–streptomycin (complete DMEM). HIV-1SF11114, a primary isolate
from a patient classified as a rapid progressor, was kindly provided by
J.A. Levy. Polyclonal antisera directed against SIVmac239 Nef was pre-
pared in rabbits (Babco) using recombinant Nef protein produced in
Escherichia coli (a generous gift from C. Morrow). A monoclonal anti-
body directed against SIV Nef (17.2) was generously provided by K.
Krohn. The rabbit anti-HIV-1SF2 Nef antibody was described previously
[21]. The anti-rat PAK-1 (PAK) polyclonal antibody, recognizing the
amino-terminal 20 amino acids, and the corresponding amino-terminal
PAK-1 competitor peptide was purchased from Santa Cruz Biotechnol-
ogy. The polyclonal antisera to human PAK65 (hPAK65) was gener-
ously provided by A. Abo [24]. A monoclonal antibody directed against
HIV-1 MA, was obtained from the ATCC.
Construction of SIVmac239 proviral clones containing
mutations in Nef
The R138R139–LL mutation, which substitutes arginine codons at posi-
tions 137 and 138 of Nef from SIVmac239 for leucine codons [22],
and the Dnef mutation [4] were subcloned into the 3′ half of the
SIVmac239 provirus. Recombinant SIVmac239nefRR–LL was produced
by cotransfecting the 5′ and 3′ proviral halves of SIVmac239 into RD-4
cells and co-cultivating them with CEMx174 lymphoid cells as previ-
ously described [44]. Virus released into the culture supernatant was
recovered after 7 days and titered by p27gag ELISA (Coulter).
Kinase assay, phosphopeptide mapping and immunoblot
analysis
Cell extraction, immunoprecipitation, SDS–PAGE and the in vitro
kinase assay were performed as described previously [21]. Procedures
for partial proteolytic cleavage and phosphopeptide mapping have
been described previously [45]. Chymotryptic digestions were per-
formed on 32P-labeled bands corresponding to p62 and p72 from Nef
and PAK immunoprecipitates. For the immunoblot analyses, PVDF
filters were washed four times with blocking buffer (Tris-buffered saline
containing 0.1 % NP40, 0.1 % Tween-20 and 0.25 % gelatin) and
probed with the anti-SIV Nef monoclonal antibody (17.2). After four
washes with blocking buffer, the membranes were incubated with a
secondary goat anti-mouse antibody conjugated with alkaline phos-
phatase (Southern Biotechnology Associates), washed four times with
blocking buffer, and twice with 100 mM Tris–HCl (pH 9.5). A
BCIP/NBT detection kit (Vector Laboratories) was used for detection.
PAK re-immunoprecipitation analysis
An in vitro kinase assay was performed on HIV-1 Nef immunoprecipi-
tates from HUT78 cells chronically infected with HIV-1SF11114 or on SIV
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Nef immunoprecipitates from CEMx174 cells chronically infected with
SIVmac239nef+. The immune complexes were incubated with kinase
extraction buffer (KEB, [21]) containing 0.1 % SDS for 1 h. The pellet
was washed three times with KEB and resuspended in SDS-gel
loading buffer (DB). To clear the supernatant of released IgG, the
supernatant was incubated twice with protein A–Sepharose. The pellet
from the second protein A–Sepharose clearance was washed twice
with KEB and resuspended in DB. The supernatant from the second
protein A–Sepharose clearance was divided equally into three tubes
and incubated with either anti-SIV Nef (control), anti-PAK-1 or anti-
hPAK65 antibodies. Immunocomplexes were collected after incubation
with protein A–Sepharose, washed three times with KEB, and resus-
pended in DB.
Infection of rhesus macaques 
All rhesus macaques (Macaca mulatta) in this study were housed in
accordance with the American Association for Accreditation of Labora-
tory Animal Care Standards (A3433-01) at the California Regional
Primate Research Center (CRPRC). Two colony-bred juvenile rhesus
macaques free of simian type D retroviruses, SIV, and STLV were inoc-
ulated intravenously with 1000 TCID50 (TCID50: 50 % of the tissue
culture infectious dose) of either SIVmac239nef+ or the mutant viruses
SIVmac239Dnef or SIVmac239nefRR–LL. The titer of each virus in this
study was measured in CEMx174 cells by end-point dilution as previ-
ously described [46]. Animals were monitored for weight loss, lym-
phadenopathy, splenomegaly and opportunistic infections; complete
differential blood counts included enumeration of CD4+ and CD8+ T
lymphocytes by flow cytometry. Infected macaques that became seri-
ously ill were humanely euthanized and necropsied. Post-mortum exam-
ination included histological analysis of all organ specimens. Detection
and quantitation of plasma antigenemia (levels of p27gag measured by
ELISA), viremia and cell-associated virus load were performed as
described previously [46,47].
Characterization of virus recovered from monkeys
Acute infections of CEMx174 cells (1 × 106) were performed using
1.0 ml of virus recovered from each monkey (macaques 26767 and
26969) at 2 and 4 weeks post-inoculation. After 5 days, infected cells
were extracted for immunoprecipitation with an anti-SIV Nef serum and
kinase assays were performed. DNA was isolated and purified from
400 ml of peripheral blood drawn from macaques 26767 and 26969 at
2, 4 and 8 weeks after infection with SIVmac239nefRR–LL. This DNA
served as a template for amplification of nef by PCR. In the first round
(30 cycles) of PCR amplification the following 5′ and 3′ primers were
used for nef: 5′–CCAGAGGCTCTCTGCGACCCTAC and 5′–AGA-
GGGCTTTAAGCAAGCAAGCGTG, respectively. For the second
round (30 cycles), the 5′ primer was the same and the 3′ primer (5′–
GCCTCTCCGCAGAGCGACTGAATAC) was used. PCR amplifica-
tions were carried out in a DNA Thermal Cycler (Perkin-Elmer Cetus)
with Taq polymerase (Perkin-Elmer). A final product of 992 base-pairs
that contained the full-length nef gene was produced. The PCR
product was cloned into pCRII (Invitrogen) and the DNA was
sequenced.
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